Trigemina is funded by private equity investors and a grant from the U.S. National Institutes of Health (NIH). Trigemina’s lead investor is Chilean-based Aurus Bios.

The Aurus Bios Fund invests primarily across the entire spectrum of life sciences, including biotechnology, pharmaceuticals, diagnostics, medical devices, human healthcare and related medical technologies, wellness and nutraceuticals, agbio, and industrial biotechnology (biomaterials/bioprocess).